SOTIO to Present New Data on the IL-15 superagonist SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
SOTIO will present three posters, including a late breaking poster on the clinical data from the ongoing Phase 1 study of IL-15 superagonist SO-C101 for the treatment of advanced solid tumors.
November 4, 2020
Source: Press Release